p53 is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells

Endocrinology

Volumn 144, Issue 1, 2003, Pages 50-60

  Polek, Tara C ^a   Stewart, Lamonica V ^a   Ryu, Elizabeth J ^a   Cohen, Michael B ^b   Allegretto, Elizabeth A ^c   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CALCITRIOL; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION;

APOPTOSIS; CALCITRIOL; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SYNERGISM; G0 PHASE; G1 PHASE; HUMANS; KI-67 ANTIGEN; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037225438     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2001-210109     Document Type: Article

References (67)

1. Colston KW, Berger U, Coombes RC 1989 Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1:188-191
2. 3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 29:161-168
3. Thomas MG, Tebbutt S, Williamson RC 1992 Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33:1660-1663
4. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
5. 3. Endocrinology 136:20-26
6. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR 1994 Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081
7. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003
8. Haussler M, Mangelsdorf DJ, Komm BS, Terpening CM, Yamazaki K, Allegretto EA, Baker AR, Shine J, McDonnell TJ, Hughes M, Weigel NL, O'Malley BW, Pike JW 1988 Molecular biology of the vitamin D hormone. In: Recent Progress in Hormone Research. New York: Academic Press, Inc.; 263-305
9. 3. Cancer Res 52:515-520
10. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
11. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL 1997 Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90
12. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ 1990 Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50:5382-5386
13. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H 1998 Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35:63-70
14. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Viru-dachalam S, Yandell DW, Weichselbaum RR 1991 Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 46:31-36
15. Carroll AG, Voeller HJ, Sugars L, Gelmann EP 1993 p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23:123-134
16. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC 1993 p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373
17. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW 1995 Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475
18. Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, Thalmann GN, Ball RK, Studer UE 1997 Abnormal p53 expression is rare in clinically localized human prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 31:209-215
19. Myers RB, Oelschlager D, Srivastava S, Grizzle WE 1994 Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243-248
20. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW 1998 Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83:2534-2539
21. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ 1993 p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669
22. Hollstein M, Sidransky D, Vogelstein B, Harris CC 1991 p53 mutations in human cancers. Science 253:49-53
23. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC 1996 Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 24:141-146
24. Donehower LA, Bradley A 1993 The tumor suppressor p53. Biochim Biophys Acta 1155:181-205
25. May P, May E 1999 Twenty years of p53 research: Structural and functional aspects of the p53 protein [published erratum appears in Oncogene 2000;19:1734]. Oncogene 18:7621-7636
26. Somasundaram K 2000 Tumor suppressor p53: Regulation and function. Front Biosci 5:D424-D437
27. 1 accumulation. Endocrinology 139:1197-1207
28. 1. Endocrinology 138:1491-1497
29. Blutt SE, McDonnell TJ, Polek TC, Weigel NL 2000 Catdtriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17
30. 3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235:539-544
31. 3 on proliferation of cancer cells in vitro. Cancer Lett 120:65-69
32. Ossovskaya VS, Mazo IA, Chemov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM, Gudkov AV 1996 Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 93:10309-10314
33. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB 2000 p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19:1959-1968
34. Nikiforov MA, Kwek SS, Mehta R, Artwohl JE, Lowe SW, Gupta TD, Deichman GI, Gudkov AV 1997 Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene 15:3007-3012
35. Gerdes J, Schwab U, Lemke H, Stein H 1983 Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20
36. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD 1991 Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873
37. Schrader M, Bendik I, Becker-Andre M, Carlberg C 1993 Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268:17830-17836
38. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15-27
39. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
40. 1 arrest in human cancer cells. Cancer Res 55:5187-5190
41. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
42. 1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 93:2721-2729
43. 3 and its analogue, EB1089, in human breast cancer cells. Oncogene 15:1555-1563
44. 3 growth inhibition in the LNCaP prostate cancer cell line through p21/waf1. J Urol 165:1319-1324
45. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmanan S 1997 Antiproliferative effects of c-myc antisense oligonudeotide in prostate cancer cells: A novel therapy in prostate cancer. Urology 50:1007-1015
46. 3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-β 2 in neuroblastoma cells. Biochem Biophys Res Commun 235:15-18
47. 3. Leuk Res 20:161-167
48. 3, retinoic acid and dexamethasone. Anticancer Drugs 4:201-208
49. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E 1995 Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis of proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55:2122-2128
50. Day ML, Zhao X, Wu S, Swanson PE, Humphrey PA 1994 Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 5:735-741
51. Welsh J 1994 Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72:537-545
52. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58:367-376
53. 3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 58:395-401
54. Mathiasen IS, Lademann U, Jaattela M 1999 Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848-4856
55. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP 1991 Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 51:3814-3817
56. Passaniti A, Isaacs JT, Haney JA, Adler SW, Cujdik TJ, Long PV, Kleinman HK 1992 Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer 51:318-324
57. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW 1991 Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753-3761
58. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW 1992 Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147:1151-1159
59. Kissmeyer AM, Binderup E, Binderup L, Mork Hansen C, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G 1997 Metabolism of the vitamin D analog EB1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 53:1087-1097
60. Cole MD 1986 The myc oncogene: Its role in transformation and differentiation. Annu Rev Genet 20:361-384
61. Dean M, Levine RA, Ran W, Kindy MS, Sonenshein GE, Campisi J 1986 Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem 261:9161-9166
62. Waters CM, Littlewood TD, Hancock DC, Moore JP, Evan GI 1991 c-myc protein expression in untransformed fibroblasts. Oncogene 6:797-805
63. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM 1997 Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8:1039-1048
64. 1. Nature 328:445-449
65. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW 2002 Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102-104
66. Itahana K, Dimri GP, Hara E, Itahana Y, Zou Y, Desprez PY, Campisi J 2002 A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem 277:18206-18214
67. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, Jaattela M 2002 Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem 277:30738-30745